Lavigne, Pierre

Professeur, Faculté de médecine et des sciences de la santé
FMSS Dép. de biochimie et de génomique fonction.

Coordonnées

Courriel


819-821-8000, poste 75462

Diplômes

(1998) Post-doctorate (Other). University of Alberta.

(1994) Doctorate (Doctor of Philosophy). Université du Québec à Trois-Rivières.

(1989) Bachelor's (Bachelor of Science). Université du Québec à Trois-Rivières.

Présentation

Sujets de recherche

Macromolecules, Modelization and Simulation, Molecular Structure and Sizing, Oncogenes, Thermodynamic Properties.

Disciplines de recherche

Biochemistry, Pharmacology.

Mots-clés

Cancer Biology, CD Spectroscopy, Molecular Recognition, NMR Spectroscopy, Protein Engineering, Protein Structure, Structural Biology, Thermodynamics, Transcription, Transcription Factors.

Intérêts de recherche

1- Development of c-Myc inhibitors, 2- Structural biology of Miz-1, 3-Structural biology of START domains, 4- Structural biology of GPCRs and 5- Structural biology of pro-Urotensin-II.

Centres de recherche

Centre de recherche du CHUS, Groupe de recherche axé sur la structure des protéines (GRASP), None.

Langues parlées et écrites

Anglais, Français

Publications

Articles de revue

  • Li X, Lavigne P, Lavoie C. (2015). *GGA3 Mediates TrkA Endocytic Recycling to PromoteSustained Akt Phosphorylation and Cell Survival. Mol Biol Cell., (In Press).
  • Domazet I, Holleran BJ, Richard A, Vandenberghe C, Lavigne P, Escher E, Leduc R, Guillemette G. (2015). *Characterization of Angiotensin II Molecular Determinants Involved in AT1 Receptor Functional Selectivity. Mol Pharmacol., 87(6), 982-95. (Published).
  • Cabana J, Holleran B, Leduc R, Escher E, Guillemette G, Lavigne P. (2015). *Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations. J. Biol. Chem., 290(25), 15835-15854. (Published).
  • Létourneau D, Lefebvre A, Lavigne P, LeHoux JG. (2015). *The binding site specificity of STARD4 subfamily: Breaking the cholesterol paradigm. Mol. Cell Endocrinol., 408, 53-61. (Published).
  • Sainsily X, Cabana J, Holeran B J, Escher E, Lavigne P, Leduc R. (2014). *Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochem. Pharmacol., 86, 1584-93. (Published).
  • Béland M , Bédard M , Tremblay G , Lavigne P , Roucou X. (2014). *Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates. Neurobiology of aging, 35(7), 1537-48. (Published).
  • Sainsily X , Cabana J , Boulais PE , Holleran BJ , Escher E , Lavigne P , Leduc R. (2013). *Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochem. Pharmacol., 86(11), 1584-93. (Published).
  • Létourneau D , Lorin A , Lefebvre A , Cabana J , Lavigne P , LeHoux JG. (2013). *Thermodynamic and solution state NMR characterization of the binding of secondary and conjugated bile acids to STARD5. Biochimica et biophysica acta, 1831(11), 1589-99. (Published).
  • Bernard D , Bédard M , Bilodeau J , Lavigne P. (2013). Structural and dynamical characterization of the Miz-1 zinc fingers 5-8 by solution-state NMR. Journal of biomolecular NMR, 57, 103-116. (Published).
  • Lorin A , Létourneau D , Lefebvre A , LeHoux JG , Lavigne P. (2013). *(1)H, (13)C, and (15)N backbone chemical shift assignments of StAR-related lipid transfer domain protein 5 (STARD5). Biomolecular NMR assignments, 7(1), 21-4. (Published).
  • Fillion D , Cabana J , Guillemette G , Leduc R , Lavigne P , Escher E. (2013). *Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode. The Journal of biological chemistry, 288(12), 8187-97. (Published).
  • Cabana J , Holleran B , Beaulieu MÈ , Leduc R , Escher E , Guillemette G , Lavigne P. (2013). *Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor. The Journal of biological chemistry, 288(4), 2593-604. (Published).
  • Létourneau D , Lefebvre A , Lavigne P , Lehoux JG. (2013). *STARD5 specific ligand binding: Comparison with STARD1 and STARD4 subfamilies. Molecular and cellular endocrinology, 371, 20-25. (Published).
  • Létourneau D , Lorin A , Lefebvre A , Frappier V , Gaudreault F , Najmanovich R , Lavigne P , LeHoux JG. (2012). *StAR-related lipid transfer domain protein 5 binds primary bile acids. Journal of lipid research, 53(12), 2677-89. (Published).
  • Bédard M , Maltais L , Beaulieu ME , Bilodeau J , Bernard D , Lavigne P. (2012). NMR structure note: solution structure of human Miz-1 zinc fingers 8 to 10. Journal of biomolecular NMR, 54(3), 317-23. (Published).
  • Beaulieu ME , McDuff FO , Frappier V , Montagne M , Naud JF , Lavigne P. (2012). New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ. Journal of molecular recognition : JMR, 25(7), 414-26. (Published).
  • Lorin A , Létourneau D , Lefebvre A , Lehoux JG , Lavigne P. (2012). *(1)H, (13)C, and (15)N backbone chemical shift assignments of StAR-related lipid transfer domain protein 5 (STARD5). Biomolecular NMR assignments, 7, 21-24. (Accepted).
  • Montagne M , Beaudoin N , Fortin D , Lavoie CL , Klinck R , Lavigne P. (2012). *The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. PLOS one, 7(2), e32172. (Published).
  • Lefrançois M , Lefebvre MR , Saint-Onge G , Boulais PE , Lamothe S , Leduc R , Lavigne P , Heveker N , Escher E. (2011). *Agonists for the Chemokine Receptor CXCR4. ACS medicinal chemistry letters, 2(8), 597-602. (Published).
  • Bilodeau J , Désilets A , McDuff FO , St-Pierre C , Barbar E , Leduc R , Lavigne P. (2011). *Influence of Ca2+ and pH on the folding of the prourotensin II precursor. FEBS letters, 585(12), 1910-4. (Published).
  • Arsenault J , Cabana J , Fillion D , Leduc R , Guillemette G , Lavigne P , Escher E. (2010). *Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism. Biochem. Pharmacol., 80(7), 990-9. (Published).
  • Arsenault J , Lehoux J , Lanthier L , Cabana J , Guillemette G , Lavigne P , Leduc R , Escher E. (2010). *A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity. Pharmacogenetics and genomics, 20(6), 377-388. (Published).
  • Fillion D , Lemieux G , Basambombo LL , Lavigne P , Guillemette G , Leduc R , Escher E. (2010). *The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. Journal of medicinal chemistry, 53(5), 2063-75. (Published).

Chapitres de livre

  • D. Létourneau, P. Lavigne, A. Lefebvre, J.-G. LeHoux. (2014). *START Domain Protein Structure and Ligand Specificity. Cholesterol Transporters of the START Domain Protein Family in Health and Disease (49-72). Springer Science. (Published).
  • M.-E. Beaulieu, F.-O. Mc Duff, M. Bédard, M. Montagne and P. Lavigne. (2013). Methods for the expression, purification, preparation and biophysical characterization of constructs of the c-Myc and Max b-HLH-LZs. Methods in Molecular Biology (7-20). Springer Science. (Published).

Autres contributions

Présentations

  • (2015). The structural biology of the Myc/Max/Mad/Miz1 network of transcription factors. Invited Lecture. Vancouver.
  • (2014). Structural Biology of the Myc/Max/Mad/Miz1 network of transcription factors and the development of Myc inhibitors. Department of Biochemistry and Molecular Biology, University of Louisville. Louisville.
  • (2014). Design of b-HLH-LZ domains that can inhibit c-Myc in vitro and in vivo. Syros Pharmaceuticals. Boston.
  • (2014). Ligand Diversity and Binding Mechanism of START Domains from the STARD4 Subfamily. Adrenal 2014. Chicago.
  • (2012). Structural Biology of the c-Myc/Max/Mad/Miz1 network: Toward the development of c-Myc inhibitors. Department of Biochemistry, University of Cambridge. Cambridge.
  • (2012). Towards the solution NMR structure of STARD6 and the discovery of new ligands of STARD5. Department of Molecular Biology and Biochemistry, Dalhousie University. Halifax.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.